findmyKOL

Douglas Simonetto, MD

Enriched profile

Associate Professor of Medicine, Transplant Hepatology · Mayo Clinic

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Rochester, MN · Midwest · United StatesSpecialtyGastroenterologyFocusLiver Disease and Transplantation+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2022–2025NIH funding2018–2026

Douglas Simonetto is Associate Professor of Medicine, Transplant Hepatology at Mayo Clinic. OpenAlex indexes 323 publications with 8,045 citations (h-index 45); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 10 Oct 2026

Overview

Updated 16 Oct 2026

Douglas Simonetto, MD, is Associate Professor of Medicine, Transplant Hepatology at Mayo Clinic, Rochester. The public record shows 323 publications with 8,045 citations (h-index 45), centered on Liver Disease and Transplantation, Alcohol Consumption and Health Effects, Liver Disease Diagnosis and Treatment. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 2 companies, 2 NIH-funded awards (2018–2026).

  • Most recent indexed publication: 2026 · Neurogastroenterology and motility
  • Top research focus: Liver Disease and Transplantation
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 2 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Brain Diseases1 trialHepatic Encephalopathy1 trialSubstance Use Disorders1 trialAlcoholism1 trialLiver Diseases1 trial

Research focus

OpenAlex concept fingerprint
Liver Disease and TransplantationAlcohol Consumption and Health EffectsLiver Disease Diagnosis and TreatmentOrgan Transplantation Techniques and OutcomesLiver physiology and pathology

Works with

trial sponsors and companies reporting payments
Novo Nordisk ASClinical trials—Industry payments6Mayo ClinicClinical trials4Industry payments—AstraZeneca UK LimitedClinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
323publications

Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.

8,045citations

Total citations across indexed works.

45h-index

Hirsch index (OpenAlex). i10-index 105.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
2companies · 2022–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2018–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 16 Oct 2026

2 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    38.7%
    Aldosterone antagonist (MRA)19.8%
    Spironolactone100%
    Part D<11 patients
    Beta blocker18.9%
    Carvedilol100%
    Part D<11 patients
  • Cancer & immunology

    27.9%
    Purine Antimetabolite15.3%
    Azathioprine100%
    Part D<11 patients
    Calcineurin inhibitor12.6%
    Tacrolimus100%
    Part D<11 patients
  • Blood & clotting

    20.7%
    Factor Xa inhibitor20.7%
    Eliquis100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)60.6% facility · 39.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

2 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:

Congress activity

Updated 16 Oct 2026

2 congress contributions (2019–2024) across ASH per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Patrick S. Kamath119Vijay H. Shah102Juan Pablo Arab39Puru Rattan28Joseph C. Ahn27Ramon A. Bataller25Andrew S. Allegretti24Daniel D. Penrice24Ashwani Kumar Singal23Ryan J. Lennon22Rakhi Maiwall22Sumeet K. Asrani21Kavish Rohit Patidar21Arun Jayant Sanyal20Guadalupe García–Tsao19Juan Pablo Roblero19Shiv Kumar Sarin18Luis Antonio Díaz17Eric S. Orman17Francisco Javier Idalsoaga16Marco A. Arrese16Sebastián Marciano16Kamalpreet S. Hara16Prasun K. Jalal16Alina M. Allen15Winston Dunn15Jorge Arnold14Pere Ginès14Nikolaos Pyrsopoulos13Alice Gallo de Moraes13Gustavo Pereira13Juan G. Abraldeṣ13Paolo Caraceni12Salvatore Silvio Piano12Brett E. Fortune12Jacqueline Córdova‐Gallardo12Camille A. Kezer12Gustavo Ayares12Stevan A. Gonzalez11Abhishek Avinash Mangaonkar11

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/douglas-simonetto-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • X / Twitter

    x.com/DougSimonetto

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • X / Twitter

    X: @DougSimonetto

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Editorial & leadership roles

journal and society appointments
  • Director

    Gastroenterology and Hepatology Fellowship Program, Mayo Clinic

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aasld.org ↗
  • Co-Director

    Data Analytics and Artificial Intelligence Laboratory, Mayo Clinic

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aasld.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.